Search academic texts

Information × Registration Number 0221U106742, 0120U104687 , R & D reports Title Study of the therapeutic effectiveness and safety of new equivalents of the dermis with the inclusion of a composite (the drug izatizon and the cytokine EMAP II) for the treatment of traumatic skin lesions popup.stage_title Head Lukash Liubov L., Доктор біологічних наук Registration Date 18-12-2021 Organization Institute of Molecular Biology and Genetics of NAS of Ukraine popup.description2 Research Objects: dermal equivalents including cell-derived component (complex of bioactive substances secreted by stem cells) and a pharmaceutical composite (isatizon drug and EMAP II cytokine); experimental model using murine ICR-IMBG strain. The main goal of the project is to create a new biotechnological product: dermal equivalents with a complex of biologically active substances synthesized by stem cells, and pharmaceutical composite (Izatizon and cytokine EMAP II) have been added, as well as in vivo studies of their therapeutic efficacy and safety. Methods: in vitro cell cultivation, animal modelling in vivo, pathophysiological, biochemical, statistical methods. All the main tasks have been completed: a new biotechnological product (dermal equivalent) has been created. Have been created samples of new dermal equivalents based on soft hydrogel including bioactive components and pharmaceutical composite. The therapeutic efficacy of these complex dermal equivalents have been shown: they promote faster and more effective healing of burn wounds in experimental animals compared with adequate control ones; as well as the lack of their acute and subchronic toxicity when administered to model animals have been shown. Clinical blood analysis of experimental animals also did not reveal abnormalities. The new biotechnological product is cheaper than world analogues and after verification in an accredited laboratory can be offered for the treatment of traumatic skin injuries in the clinic. Key words: dermal equivalent, thermal burn disease, complex of biologically active substances secreted by MSC, izatizon, EMAP II. Product Description popup.authors Zaika Leonid A. Kolomiiets Lesia A. Korneliuk Oleksandr I Macewicz Larysa Leonidivna Papuga Olexander Yevgeniiovych Ruban Tetyana P. popup.nrat_date 2021-12-18 Close